AcouSort AB (ACOU) - Total Liabilities

Latest as of March 2026: Skr12.79 Million SEK ≈ $1.38 Million USD

Based on the latest financial reports, AcouSort AB (ACOU) has total liabilities worth Skr12.79 Million SEK (≈ $1.38 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ACOU working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

AcouSort AB - Total Liabilities Trend (2013–2025)

This chart illustrates how AcouSort AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see AcouSort AB (ACOU) total assets.

AcouSort AB Competitors by Total Liabilities

The table below lists competitors of AcouSort AB ranked by their total liabilities.

Company Country Total Liabilities
Filtronic
LSE:FTC
UK GBX14.42 Million
VinaCapital Vietnam Opportunity Fund
LSE:VOF
UK GBX38.47 Million
Rossi Residencial S.A
SA:RSID3
Brazil R$1.21 Billion
Academies Australasia Group Ltd
AU:AKG
Australia AU$54.87 Million
X2M Connect Ltd
AU:X2M
Australia AU$9.26 Million
Teamo Productions HQ Limited
NSE:TPHQ
India Rs173.29 Million
Strategic Energy Resources Limited
F:EB8
Germany €842.74K
Altheora SA
PA:ALORA
France €23.25 Million

Liability Composition Analysis (2013–2025)

This chart breaks down AcouSort AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ACOU equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.69 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.93 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.48 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how AcouSort AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for AcouSort AB (2013–2025)

The table below shows the annual total liabilities of AcouSort AB from 2013 to 2025.

Year Total Liabilities Change
2025-12-31 Skr1.59 Million
≈ $171.32K
-58.77%
2024-12-31 Skr3.86 Million
≈ $415.51K
-62.80%
2023-12-31 Skr10.38 Million
≈ $1.12 Million
-53.96%
2022-12-31 Skr22.54 Million
≈ $2.43 Million
+537.14%
2021-12-31 Skr3.54 Million
≈ $380.75K
-1.15%
2020-12-31 Skr3.58 Million
≈ $385.16K
+69.38%
2019-12-31 Skr2.11 Million
≈ $227.39K
+13.60%
2018-12-31 Skr1.86 Million
≈ $200.17K
+74.81%
2017-12-31 Skr1.06 Million
≈ $114.50K
-48.94%
2016-12-31 Skr2.08 Million
≈ $224.27K
+1044.60%
2015-12-31 Skr182.07K
≈ $19.59K
-66.51%
2014-12-31 Skr543.60K
≈ $58.50K
-74.88%
2013-12-31 Skr2.16 Million
≈ $232.88K
--

About AcouSort AB

ST:ACOU Sweden Biotechnology
Market Cap
$6.29 Million
Skr58.41 Million SEK
Market Cap Rank
#28211 Global
#621 in Sweden
Share Price
Skr2.76
Change (1 day)
+2.99%
52-Week Range
Skr2.13 - Skr4.99
All Time High
Skr31.61
About

AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, a module that enables in-line analysis of blood plasma from whole blood samples; Acous… Read more